Modifying the substrate specificity of carcinoscorpius rotundicauda serine protease inhibitor domain 1 to target thrombin

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Giri, Pankaj Kumar ^a   Tang, Xuhua ^a   Thangamani, Saravanan ^a,b   Shenoy, Rajesh T ^a   Ding, Jeak Ling ^a   Swaminathan, Kunchithapadam ^a   Sivaraman, J ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHODNIIN; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 1 DOMAIN 1; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; SERINE; THROMBIN; TRYPSIN;

ARTICLE; BLOOD CELL; CARCINOSCORPIUS ROTUNDICAUDA; CIRCULAR DICHROISM; CONTROLLED STUDY; CRAB; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENANTIOSELECTIVITY; ENZYME SPECIFICITY; GENE MUTATION; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR DYNAMICS; NONHUMAN; PLASMID; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STRUCTURAL HOMOLOGY; WILD TYPE; ANIMAL; CALORIMETRY; CHEMISTRY; ENZYME ACTIVE SITE; ENZYMOLOGY; HYDROGEN BOND; IC 50; LIMULUS; METHODOLOGY; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

CARCINOSCORPIUS ROTUNDICAUDA; INVERTEBRATA; MEROSTOMATA;

ANIMALS; CALORIMETRY; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HORSESHOE CRABS; HYDROGEN BONDING; INHIBITORY CONCENTRATION 50; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SERINE; SERINE PROTEINASE INHIBITORS; SUBSTRATE SPECIFICITY; THROMBIN; TRYPSIN;

EID: 78650863682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015258     Document Type: Article

References (36)

1. Hoebe K, Janssen E, Beutler B (2004) The interface between innate and adaptive immunity. Nat Immunol 5: 971-974.
2. Muta T, Iwanaga S (1996) The role of hemolymph coagulation in innate immunity. Curr Opin Immunol 8: 41-47.
3. Armstrong PB (2001) The contribution of proteinase inhibitors to immune defense. Trends Immunol 22: 47-52.
4. Ding JL, Navas MA, 3rd, Ho B (1993) Two forms of factor C from the amoebocytes of Carcinoscorpius rotundicauda: purification and characterisation. Biochim Biophys Acta 1202: 149-156.
5. Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102: 4751-4804.
6. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA (1999) Phylogenetic perspectives in innate immunity. Science 284: 1313-1318.
7. Salzet M (2001) Vertebrate innate immunity resembles a mosaic of invertebrate immune responses. Trends Immunol 22: 285-288.
8. Hemmi H, Kumazaki T, Yoshizawa-Kumagaye K, Nishiuchi Y, Yoshida T, et al. (2005) Structural and functional study of an Anemonia elastase inhibitor, a ''nonclassical'' Kazal-type inhibitor from Anemonia sulcata. Biochemistry 44: 9626-9636.
9. Kanost MR (1999) Serine proteinase inhibitors in arthropod immunity. Dev Comp Immunol 23: 291-301.
10. Jiang N, Thangamani S, Chor CF, Wang SY, Winarsih I, et al. (2009) A novel serine protease inhibitor acts as an immunomodulatory switch while maintaining homeostasis. J Innate Immun 1: 465-479.
11. van de Locht A, Lamba D, Bauer M, Huber R, Friedrich T, et al. (1995) Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J 14: 5149-5157.
12. Rydel TJ, Tulinsky A, Bode W, Huber R (1991) Refined structure of the hirudin-thrombin complex. J Mol Biol 221: 583-601.
13. Gurm HS, Bhatt DL (2005) Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. Am Heart J 149: S43-53.
14. Steinmetzer T, Hauptmann J, Sturzebecher J (2001) Advances in the development of thrombin inhibitors. Expert Opin Investig Drugs 10: 845-864.
15. Markwardt F (2002) Historical perspective of the development of thrombin inhibitors. Pathophysiol Haemost Thromb 32 Suppl 3: 15-22.
16. Drag M, Salvesen GS (2010) Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9: 690-701.
17. Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
18. Vacca JP (2000) New advances in the discovery of thrombin and factor Xa inhibitors. Curr Opin Chem Biol 4: 394-400.
19. Weitz JI, Crowther M (2002) Direct thrombin inhibitors. Thromb Res 106: V275-284.
20. Pfau R (2003) Structure-based design of thrombin inhibitors. Curr Opin Drug Discov Devel 6: 437-450.
21. Holm L, Sander C (1998) Touring protein fold space with Dali/FSSP. Nucleic Acids Res 26: 316-319.
22. Maynes JT, Cherney MM, Qasim MA, Laskowski M, Jr., James MN (2005) Structure of the subtilisin Carlsberg-OMTKY3 complex reveals two different ovomucoid conformations. Acta Crystallogr D Biol Crystallogr 61: 580-588.
23. Lombardi A, De Simone G, Galdiero S, Staiano N, Nastri F, et al. (1999) From natural to synthetic multisite thrombin inhibitors. Biopolymers 51: 19-39.
24. Markwardt F (1994) The development of hirudin as an antithrombotic drug. Thromb Res 74: 1-23.
25. Ikeo K, Takahashi K, Gojobori T (1995) Different evolutionary histories of kringle and protease domains in serine proteases: a typical example of domain evolution. J Mol Evol 40: 331-336.
26. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Macromolecular Crystallography 276 Pt A: 307-326.
27. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
28. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
29. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
30. Ochman H, Gerber AS, Hartl DL (1988) Genetic applications of an inverse polymerase chain reaction. Genetics 120: 621-623.
31. DeLano WL, Lam JW (2005) PyMOL: A communications tool for computational models. Abstracts of Papers of the American Chemical Society 230: U1371-U1372.
32. Gouet P, Courcelle E, Stuart DI, Metoz F (1999) ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 15: 305-308.
33. Stubbs MT, Morenweiser R, Sturzebecher J, Bauer M, Bode W, et al. (1997) The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin. Implications for the structure of human mast cell tryptase and its inhibition. J Biol Chem 272: 19931-19937.
34. Barrette-Ng IH, Ng KK, Cherney MM, Pearce G, Ghani U, et al. (2003) Unbound form of tomato inhibitor-II reveals interdomain flexibility and conformational variability in the reactive site loops. J Biol Chem 278: 31391-31400.
35. Richer MJ, Keays CA, Waterhouse J, Minhas J, Hashimoto C, et al. (2004) The Spn4 gene of Drosophila encodes a potent furin-directed secretory pathway serpin. Proc Natl Acad Sci U S A 101: 10560-10565.
36. Leblond J, Laprise MH, Gaudreau S, Grondin F, Kisiel W, et al. (2006) The serpin proteinase inhibitor 8: an endogenous furin inhibitor released from human platelets. Thromb Haemost 95: 243-252.